Autism: a curse on today’s society
Keywords:Autism, autism spectrum disorder, diagnosis for autism, time required for autism diagnosis, diagnosis of autism age wise, treatments for autism
Autism is a group of neurodevelopment disorders characterized by impaired communication, impaired social interaction and restricted, repetitive and stereotyped patterns of behaviours or interests in the first 3 years of life. It shows a strong male bias and found four times more in males than in females. According to a study in the US, in 2014, overall 1.68% of victims were reported to have Autism Spectrum Disorder (ASD), whereas the percentage was increased by 15% and 150% respectively over the year 2012 and 2000. Numerous genes have been discovered that have roles in ASD but still a good understanding of the pathophysiological process of ASD is not established. ASD costs are estimated to be approximately $250 billion annually in the U.S. Moreover, it is suggested that by 2025, ASD costs will rise to over $450 billion. Thus, the financial burden on families is increasing. There is no effective screening tool for proper diagnosis is available. Based on Infant Toddler Checklist (ITC) and Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) some tests like ADOS-G, ADI-R, CARS etc. are used for diagnosis. There are medications to cure symptoms but no single medication for ASD. However, some therapies (like ABA- Applied Behavioural Analysis, DTT- Discrete Trial Training, and Symptomatic treatments, etc.) are there that show positive responses towards improvement from a disease state. Some crucial advancement has been achieved in the last decades. Here in the work we have focused on the diagnostic methods and treatment available for the symptoms of Autism. So, it can be said that the day is not too far away when the remedy to cut the curse of autism will be in our hands.
Hadeel F, Nahed Al A, Lee T. Autism spectrum disorders. Annals of Saudi Medicine, 30(4) 295-300(2010).
American Psychiatric Association. “Diagnostic and statistical manual of mental disorders.” https://www.psychiatry.org/psychiatrists/practice/dsm,3rd ed, Cited in 1980.
Mattila ML, Kielinen M, Linna SL, Jussila K, Ebeling H, Bloigu R, Joseph RM, Moilanen I. Autism spectrum disorders according to DSM-IV-TR and comparison with DSM-5 draft criteria: an epidemiological study. Journal of American Academy Child Adolescent Psychiatry, 50, 583-592 (2011).
Kim YS, Leventhal BL, Koh YJ, Fombonne E, Laska E, Lim EC, Cheon KA, Kim SJ, Kim YK, Lee H, Song DH, Grinker RR. Prevalence of autism spectrum disorders in a total population sample. The American Journal of Psychiatry, 168, 904-912 (2011).
Fisch GS. Nosology and epidemiology in autism: classification counts. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 160C, 91-103 (2012).
Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C, Montiel-Nava C, Patel V, Paula CS, Wang C, Yasamy MT, Fombonne E. Global prevalence of autism and other pervasive developmental disorders. Autism Research: official journal of the International Society for Autism Research, 5, 160-179 (2012).
Fombonne E. Incidence and prevalence of pervasive developmental disorders. Pediatric Research, 65(6), 591-8 (2009)
Werling DM, Geschwind DH. Sex differences in autism spectrum disorders. Current Opinion Neurology, 26, 146–153 (2013).
Baron-Cohen S, Lombardo MV, Auyeung B, Ashwin E, Chakrabarti B, Knickmeyer R. Why are autism spectrum conditions more prevalent in males?. PLoS Biology, 9(6), (2011).
Robinson EB, Lichtenstein P, Anckarsäter H, Happé F, Ronald A. Examining and interpreting the female protective effect against autistic behaviour. Proceedings of the National Academy of Sciences of the United States America, 110, 5258-5262 (2013).
Rogers SJ. Developmental regression in autism spectrum disorder. Mental Retardation and Developmental Disabilities Research Reviews, 10, 139–143 (2004).
Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1211–59 (2017).
Hay SI, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1260–344(2017).
Lai MC, Baron-Cohen S. Identifying the lost generation of adults with autism spectrum conditions. The Lancet Psychiatry, 11, 1013-27 (2015).
Baio J, Wiggins L, Christensen DL, Maenner MJ, Daniels J, Warren Z, et al. Prevalence of autism spectrum disorder among children aged 8 years–autism and developmental disabilities monitoring network, 11 sites, United States, 2014. Morbidity and Mortality Weekly Report Surveillance Summary (Washington, D.C.: 2002), 67, 1–23(2018).
Lyall K, Croen L, Daniels J, Fallin MD, Ladd-Acosta C, Lee B, Park BY, Snyder NW, Schendel D, Volk H et al. The changing epidemiology of autism spectrum disorders. Annual Review of Public Health, 38, 81–102 (2017).
Bleuler E. The theory of schizophrenic negativism. The Journal of Nervous and Mental Disease Publishing Company, 39 (1), 50-57(1912).
Asperger H. Die "AutistischenPsychopathen" imKindesalter. Arch Psychiatr Nervenkr, 117, 76-136 (1944).
Kanner L. Autistic disturbances of affective contact. Nervous Child, 2, 217-250 (1943).
Bailey A, Le Couteur A, Gottesman, Bolton P, Simonoff E, Yuzda E, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychological Medicine, 25, 63-77 (1995).
Herman GE, Henninger N, Ratliff-Schaub K, Pastore M, Fitzgerald S, McBride KL. Genetic testing in autism: how much is enough?. Genetics in Medicine: The official journal of the American College of Medical Genetics, 9, 268-274 (2007).
Miles JH. Autism spectrum disorders--a genetics review. Genetics in Medicine: The official journal of the American College of Medical Genetics, 13, 278-294 (2011).
Szatmari P, Jones MB, Zwaigenbaum L, MacLean JE. Genetics of autism: overview and new directions. Journal of Autism and Developmental Disorders, 28, 351-368 (1998).
Chang J, Gilman SR, Chiang AH, Sanders SJ, Vitkup D. Genotype to phenotype relationships in autism spectrum disorders. Nature Neuroscience, 18, 191-198 (2015).
Geschwind DH. Genetics of autism spectrum disorders. Trends in Cognitive Sciences, 15,409-416 (2011).
Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor RM, Blencowe BJ, Geschwind DH. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature, 474, 380-384 (2011).
Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in malesand females with fragile X full mutation and permutation. Journal of Autism and Developmental Disorders, 37,738-747 (2007).
Curatolo P, Bombardieri R. Tuberous sclerosis. Handbook of Clinical Neurology, 87, 129-151 (2008).
Curatolo P, Moavero R, de Vries PJ. Neurological and neuropsychiatric aspects of tuberous sclerosis complex. The Lancet Neurology, 14, 733–45 (2015).
Kim YS, Leventha BL. Genetic epidemiology and insights into interactive genetic and environmental effects in autism spectrum disorders. Biological Psychiatry, 77, 66–74 (2015).
Lyall K, Croen L, Daniels J, Fallin MD, Ladd-Acosta C, Lee BK, et al. The changing epidemiology of autism spectrum disorders. Annual Review of Public Health, 38, 81–102 (2017).
EmbertiGialloreti L, Benvenuto A, Benassi F, Curatolo P. Are caesarean sections, induced labor and oxytocin regulation linked to autism spectrum disorders?. Medical Hypotheses, 82(6), 713–8 (2014).
Buie T. Potential etiologic factors of microbiome disruption in autism. Clinical Therapeutics, 37, 976–83 (2015).
Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Archives of General Psychiatry, 68, 1095–102 (2011).
Zwaigenbaum L, Bryson S, Rogers T, Roberts W, Brian J, Szatmari P. Behavioral manifestations of autism in the first year of life. International Journal of Developmental Neuroscience: The official journal of the International Society for Developmental Neuroscience, 23, 143-152 (2005).
Randall M, Egberts KJ, Samtani A, Scholten RJPM, Hooft L, Livingstone N, Sterling-Levis K, Woolfenden S, Williams K. Diagnostic test for Autism Spectrum Disorder (ASD) in preschool Children. The Cochrane Database of Systemic Reviews, 7, CD009044 (2018).
Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. Journal of Autism and Developmental Disorders, 30(3), 205-23 (2000).
Oosterling I, Rommelse N, de Jonge M, van der Gaag RJ, Swinkels S, Roos S, et al. How useful is the Social Communication Questionnaire in toddlers at risk of autism spectrum disorder?. The Journal of Child Psychology and Psychiatry, and allied disciplines, 51(11), 1260–8 (2010).
Sarah Carrington, Susan Leekam, Rachel Kent, Jarymke Maljaars, Judith Gould, Lorna Wing, Ann Le Couteur, Ina Van Berckelaer-Onnes, IlseNoens. Signposting for diagnosis of Autism Spectrum Disorder using the Diagnostic Interview for Social and Communication Disorders (DISCO). The Journal of Child Psychology and Psychiatry, and allied disciplines, 9 (2015), 45–52 (2015)
Skuse D, Warrington R, Bishop D, Chowdhury U, Lau J, Mandy W, Place M. The developmental, dimensional and diagnostic interview (3di): a novel computerized assessment for autism spectrum disorders. Journal of American Academy Child & Adolescent Psychiatry, 43(5), 548-58 (2004).
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. The New England Journal of Medicine, 347,314-21(2002).
Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatric Disease and Treatment, 4, 723-30 (2008).
Posey DJ, McDougle CJ. Pharmacotherapeutic management of autism. Expert Opinion on Pharmacotherapy, 2, 587- 600 (2001).
Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Molecular Psychiatry, 21, 1225–1231 (2016).
McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, et al. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics, 127, e1312–e1321 (2011).
Siegel M, Beaulieu AA. Psychotropic medications in children with autism spectrum disorders: a systematic review and synthesis for evidence-based practice. Journal of Autism and Developmental Disorders, 42, 1592–1605 (2012).
Barbaresi WJ, Katusic SK, Voigt RG. Autism: a review of the state of the science for pediatric primary health care clinicians. Archive of Pediatrics & Adolescent Medicine, 160, 1167-75 (2006).
Kaneen B. Geiger, James E. Carr, Linda A. LeBlanc, Nicole M. Hanney, Amy S. Polick, Megan R. Heinicke. Teaching Receptive Discriminations to Children with Autism: A Comparison of Traditional and Embedded Discrete Trial Teaching. Association for Behaviour Analysis International, 5(2), 49–592012.
Brian Reichow, Kara Hume, Erin E Barton, Brian A Boyd. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Systematic Reviews, 2018(5), CD009260 (2018)
Linda A LeBlanc, John Esch, Tina M Sidener, Amanda M Firth. Behavioral Language Interventions for Children with Autism: Comparing Applied Verbal Behavior and Naturalistic Teaching Approaches. Association for Behaviour Analysis International, 22(1), 49–60 (2006).
Jiedi Lei, Pamela Ventola. Pivotal response treatment for autism spectrum disorder: current perspectives. Neuropsychiatric Disease and Treatment, 13, 1613–1626 (2017).
Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634-41 (2004).
Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of American Academy Child & Adolescent Psychiatry, 48, 1110-1119 (2009).
Myers SM, Johnson CP, Lipkin PH, et al. Management of children with autism spectrum Disorders. Pediatrics, 120, 1162 (2007).
Ozonoff S, Cathcart K. Effectiveness of a home program intervention for young children with Autism. Journal of Autism and Developmental Disorders, 28, 25-32 (1998).
CP Lipkin PH, et al. Management of children with autism spectrum disorders. Pediatrics, 120, 1162 (2007).
Srinivas Medavarapu, Lakshmi Lavanya Marella , Aneela Sangem , Ram Kairam. Where is the Evidence? A Narrative Literature Review of the Treatment Modalities for Autism Spectrum Disorders. Cureus, 11(1), e3901 (2019)
Mahoney G, Perales F. Relationship-focused early intervention with children with pervasive developmental disorders and other disabilities: a comparative study. Journal of Developmental Behavioural Pediatrics, 26, 77-85 (2005).
Howlin P, Gordon RK, Pasco G, Wade A, Charman T. The effectiveness of Picture Exchange Communication System (PECS) training for teachers of children with autism: a pragmatic, group randomised controlled trial. Journal of Child Psychology and Psychiatry, and allied disciplines, 48, 473-481 (2007).
Brian JA, Smith IM, Zwaigenbaum L, Roberts W, Bryson SE. The Social ABCs caregiver mediated intervention for toddlers with autism spectrum disorder: feasibility, acceptability, and evidence of promise from a multisite study. Autism Research, 8,899-912 (2016).
Green J, Charman T, McConachie H, et al. Parent-mediated communication-focused treatment in children with autism (PACT): a randomised controlled trial. Lancet, 375, 2152-2160 (2010).
Kasari C, Lawton K, Shih W, et al. Caregiver-mediated intervention for low-resourced preschoolers with autism: an RCT. Pediatrics, 134, e72-9 (2014).
Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, Greenhill L. Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorder, 25, 283-94 (1995).
Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. The Journal of Clinical Psychiatry, 53, 77-82 (1992).
Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology, 30, 582-589 (2005)
How to Cite
Copyright (c) 2020 Snehashis Sarkar, Ananta Choudhury, Suman Saha, Biplab Kumar Dey
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
In submitting an article to Journal of Applied Pharmaceutical Research (JOAPR) I certify that:
- I am authorized by my co-authors to enter into these arrangements.
- I warrant, on behalf of myself and my co-authors, that:
- the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights;
- I am/we are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to JOAPR are not in breach of any other obligation;
- the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy;
- I/we have taken due care to ensure the integrity of the article. To my/our - and currently accepted scientific - knowledge all statements contained in it purporting to be facts are true and any formula or instruction contained in the article will not, if followed accurately, cause any injury, illness or damage to the user.
- I, and all co-authors, agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution-NonCommercial 4.0 International License
- I, and all co-authors, agree that, if the article is editorially accepted for publication in Journal of Applied Pharmaceutical Research (JOAPR) data included in the article shall be made available under the Creative Commons 1.0 Public Domain Dedication waiver, unless otherwise stated. For the avoidance of doubt it is stated that sections 1, 2, and 3 of this license agreement shall apply and prevail.